Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
57.18 BRL | -0.16% | -1.50% | +14.47% |
22/05 | Sandoz: Marketing authorization for Wyost and Jubbonti in the EU | CF |
22/05 | Roche Gets US FDA Breakthrough Designation For Lipoprotein(a) Test | MT |
Sales 2024 * | 33B 170B 2,746B | Sales 2025 * | 33.96B 175B 2,826B | Capitalization | 166B 856B 13,811B |
---|---|---|---|---|---|
Net income 2024 * | 4.13B 21.31B 344B | Net income 2025 * | 6.61B 34.09B 550B | EV / Sales 2024 * | 6.5 x |
Net Debt 2024 * | 48.46B 250B 4,032B | Net Debt 2025 * | 43.54B 225B 3,623B | EV / Sales 2025 * | 6.17 x |
P/E ratio 2024 * |
38.9
x | P/E ratio 2025 * |
24.7
x | Employees | 26,700 |
Yield 2024 * |
2.98% | Yield 2025 * |
3.23% | Free-Float | 99.75% |
Latest transcript on Amgen Inc.
1 day | -0.16% | ||
1 week | -1.50% | ||
Current month | +12.21% | ||
1 month | +15.00% | ||
3 months | +13.23% | ||
6 months | +24.82% | ||
Current year | +14.47% |
Managers | Title | Age | Since |
---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 61 | 01/06/01 |
Peter Griffith
DFI | Director of Finance/CFO | 65 | 23/19/23 |
James Bradner
CTO | Chief Tech/Sci/R&D Officer | 52 | 18/12 |
Members of the board | Title | Age | Since |
---|---|---|---|
Charles Holley
BRD | Director/Board Member | 67 | 03/17/03 |
Ellen Kullman
BRD | Director/Board Member | 68 | 14/16/14 |
Robert Williams
BRD | Director/Board Member | 75 | 17/14/17 |
Date | Price | Change | Volume |
---|---|---|---|
21/24/21 | 57.18 | -0.16% | 15 |
20/24/20 | 57.27 | -1.34% | 23 |
15/24/15 | 58.05 | +1.79% | 9 |
14/24/14 | 57.03 | +0.90% | 25 |
Delayed Quote Sao Paulo, May 22, 2024 at 12:10 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+37.74% | 723B | |
+34.36% | 595B | |
-2.07% | 369B | |
+20.25% | 332B | |
+2.99% | 282B | |
+17.09% | 244B | |
+9.80% | 208B | |
-4.46% | 205B | |
+2.81% | 168B |
- Stock Market
- Equities
- AMGN Stock
- AMGN34 Stock